This month

The FDA moved on GHK-Cu in April — and the internet misread every word of it.

In April 2026, the FDA announced the removal of 12 peptide bulk drug substances from Category 2 of its Section 503A bulk drug substances list. GHK-Cu — the copper-binding tripeptide that has dominated the skincare-peptide crossover space for the better part of this year — was among them. TikTok ran with it as a clearance. Wellness creators called it a win. Posts tallying millions of views framed the FDA's action as the agency finally stepping back from one of its most contested compounding restrictions. The actual regulatory mechanics are more specific and less satisfying than that story. According to [law firm Orrick's April 2026 summary of the FDA announcement](https://www.orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings), removal from Category 2 does not place GHK-Cu on the authorized 503A bulk drug substances list — it removes it from the don't-compound category while leaving it in regulatory limbo. The Pharmacy Compounding Advisory Committee is now scheduled to formally review GHK-Cu's status before February 2027, and that review — not the April paperwork — is what will determine whether compounding pharmacies can legally prepare it at scale. GHK-Cu also remains outside the FDA's current interim enforcement discretion policy, which only applies to Category 1 substances. What changed last month was not a green light. What changed is that the question is formally queued.

The actual biology

A copper carrier peptide with more mechanistic substance than the skincare aisle implies.

GHK stands for glycine-histidine-lysine, a tripeptide that occurs naturally in human plasma, saliva, and urine. The Cu is copper(II), which the peptide binds and transports. Online, the mechanism gets compressed into outcome claims: more collagen, tighter skin, faster wound closure. The underlying biology is less theatrical but more defensible. GHK-Cu has been shown in laboratory and gene-expression research to influence the regulation of extracellular matrix proteins, activate transcription related to collagen and glycosaminoglycan synthesis, and down-regulate matrix metalloproteinases — the enzymes that degrade connective tissue. The copper component is not cosmetic decoration: copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin fibers. A [2019 NIH review published in PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/) documented GHK-Cu's broad influence on gene regulation, covering more than 4,000 human genes across wound healing, anti-inflammatory, and tissue-remodeling categories. The mechanistic story is coherent. The distance between coherent mechanism and clinically proven systemic outcome is where the article typically ends before it should.

The public story

TikTok collapses the gap between a serum and an injectable — and that gap is substantial.

The GHK-Cu conversation online runs between two audiences that rarely acknowledge each other's existence. In skincare circles, it has been a dermatologist-adjacent ingredient for years — showing up in premium serums and post-procedure protocols. In peptide-therapy spaces, it is reframed as a systemic optimization candidate, often stacked beside BPC-157 and epitalon in longevity discussions. The TikTok moment blends both. Creators move from before-and-after skin photos from a topical serum to injectable peptide therapy in the same scroll, as if the route of administration were a minor variable. It is not. A topical application at sub-one-percent concentration exists in a completely different pharmacokinetic and regulatory universe than an injectable preparation. The FDA's April 2026 action was specifically about injectable GHK-Cu compounding — not skincare serums, which are in a separate regulatory category entirely. The TikTok blending of these two things is not deceptive by intent; it is a category error by default. And it is the reason the April regulatory news registered as more significant than the mechanics support. The celebration is about a document that says it's no longer on the don't-compound list, not one that says what the evidence shows.

What the data says

Human evidence exists — mostly in dermatology contexts, not systemic longevity ones.

GHK-Cu's Early human evidence tier reflects a real, if narrow, clinical foundation. Topical studies in dermatology settings have documented measurable effects. A human study evaluated copper tripeptide complex following CO2 laser resurfacing, showing improved wound healing outcomes — published in the [Archives of Facial Plastic Surgery](https://www.liebertpub.com/abs/doi/10.1001/archfaci.8.4.252). A clinical trial cited by [EurekAlert](https://www.eurekalert.org/news-releases/990464) found that GHK-Cu activated epigenetic mechanisms associated with increased collagen density in skin. The [PubMed literature trail](https://pubmed.ncbi.nlm.nih.gov/?term=GHK-Cu+copper+tripeptide) documents a consistent pattern across multiple study types: topical GHK-Cu in post-procedure, wound-healing, and photoaged-skin contexts shows measurable signal. Preclinical work adds further mechanistic data around gene expression and matrix remodeling. What the evidence trail does not support is the leap from topical skin data to injectable systemic aging claims. The evidence base is for specific topical endpoints. Systemic or longevity claims require their own clinical evidence, which does not currently exist in any mature form. That gap is also why the PCAC review evaluating injectable GHK-Cu's safety and clinical rationale has not happened yet — the committee is being asked to evaluate evidence that the compounding market has been operating ahead of.

PeptideFactCheck stance

Early human evidence, earned — and a regulatory story with a 2027 deadline.

GHK-Cu earns the Early human evidence tier because the dermatology studies are real, not because the broader claims have been validated. The distinction holds in May 2026 more than it usually does, because the regulatory moment has created enough public noise that the nuances are getting compressed. What is true: this peptide has a more credible scientific foundation than most ingredients in its category, the mechanism is coherent, and the compounding regulatory question now has a formal timeline. What is not true: that the April 2026 FDA paperwork validated injectable GHK-Cu, that Category 2 removal equals clinical clearance, or that the systemic longevity claims have crossed any evidentiary threshold. The PCAC review before February 2027 is the next meaningful regulatory moment for this peptide. If it results in GHK-Cu being added to the 503A bulk substances list, that changes the compounding landscape — not the evidence tier. Evidence tiers move when clinical data matures. That process moves slower than TikTok, and on purpose.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.